Macdot-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated for the management of allergic conditions. Levocetirizine is a potent, selective second-generation antihistamine that inhibits peripheral H1 receptors, effectively reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the action of cysteinyl leukotrienes, which are inflammatory mediators involved in bronchoconstriction, mucus secretion, and airway edema, thereby providing relief in allergic asthma and seasonal allergic rhinitis. The combined action of Levocetirizine and Montelukast offers a comprehensive approach to allergy management by targeting multiple pathways in the allergic response. Macdot-M is indicated for patients requiring symptomatic relief from allergic rhinitis, chronic urticaria, and asthma prophylaxis. It is generally well-tolerated, with a low incidence of sedation due to the non-sedating nature of Levocetirizine. Dosage should be as prescribed by a healthcare professional, considering patient-specific factors. Caution is advised in patients with hepatic or renal impairment. This combination therapy enhances patient compliance by reducing pill burden while providing effective symptom control.